{"transactions":[{"id":712021,"issuer":{"id":6649,"kind":"organization","name":"Quanterix Corp","symbol":"QTRX"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-07-09T21:19:21.000Z","date":"2026-07-08","kind":"exercise","planned":false,"acquired":false,"shares":8073,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 8, 2025, the reporting person was granted 24,464 restricted stock units, vesting 33%, 33%, and 34% on the first, second, and third anniversaries of the grant date, respectively."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On July 8, 2025, the reporting person was granted 24,464 restricted stock units, vesting 33%, 33%, and 34% on the first, second, and third anniversaries of the grant date, respectively."}],"balance_after":16391,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8073},"source":{"system":"sec-edgar","filing":"0001168581-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1168581/000116858126000002/primarydocument.xml","form_type":"4"}},{"id":712020,"issuer":{"id":6649,"kind":"organization","name":"Quanterix Corp","symbol":"QTRX"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-09T21:19:21.000Z","date":"2026-07-08","kind":"exercise","planned":false,"acquired":true,"shares":8073,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":15041,"source":{"system":"sec-edgar","filing":"0001168581-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1168581/000116858126000002/primarydocument.xml","form_type":"4"}},{"id":790773,"issuer":{"id":3201,"kind":"organization","name":"WEST PHARMACEUTICAL SERVICES INC","symbol":"WST"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-06T21:32:27.000Z","date":"2026-05-04","kind":"grant","planned":false,"acquired":true,"shares":791,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors."}],"balance_after":20434.587,"source":{"system":"sec-edgar","filing":"0000105770-26-000063","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000063/form4.xml","form_type":"4"}},{"id":947526,"issuer":{"id":6649,"kind":"organization","name":"Quanterix Corp","symbol":"QTRX"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T22:46:17.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":1944,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the fourth quarter of 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 47,836 restricted stock units."}],"balance_after":54804,"source":{"system":"sec-edgar","filing":"0001168581-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1168581/000116858126000001/primarydocument.xml","form_type":"4"}},{"id":947525,"issuer":{"id":6649,"kind":"organization","name":"Quanterix Corp","symbol":"QTRX"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T22:46:17.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":23372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest as to 100% of the shares on January 2, 2027 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 47,836 restricted stock units."}],"balance_after":52860,"source":{"system":"sec-edgar","filing":"0001168581-26-000001","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1168581/000116858126000001/primarydocument.xml","form_type":"4"}},{"id":1025192,"issuer":{"id":6649,"kind":"organization","name":"Quanterix Corp","symbol":"QTRX"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-04T00:54:36.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":2084,"price":5.54,"value":11545.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third quarter of 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Closing price of the Company's common stock on the Nasdaq Global Market on October 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 24,464 restricted stock units."}],"balance_after":29488,"source":{"system":"sec-edgar","filing":"0001168581-25-000003","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1168581/000116858125000003/primarydocument.xml","form_type":"4"}},{"id":1089579,"issuer":{"id":6649,"kind":"organization","name":"Quanterix Corp","symbol":"QTRX"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-11T00:39:39.000Z","date":"2025-07-08","kind":"grant","planned":false,"acquired":true,"shares":50758,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests as to one-third of the shares on July 8, 2026, and the remaining two-thirds of the shares vest monthly thereafter over two years in 24 successive equal installments."}],"balance_after":50758,"derivative":{"exercise_price":6.54,"expiration_date":"2035-07-08","underlying":"Common Stock","underlying_shares":50578},"source":{"system":"sec-edgar","filing":"0001562180-25-005380","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1168581/000156218025005380/primarydocument.xml","form_type":"4"}},{"id":1089578,"issuer":{"id":6649,"kind":"organization","name":"Quanterix Corp","symbol":"QTRX"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-11T00:39:39.000Z","date":"2025-07-08","kind":"grant","planned":false,"acquired":true,"shares":24464,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of stock issuable on vesting of restricted stock units. The restricted stock units vest as to one-third of the shares on each of July 8, 2026, July 8, 2027 and July 8, 2028."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 24,464 restricted stock units."}],"balance_after":27404,"source":{"system":"sec-edgar","filing":"0001562180-25-005380","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1168581/000156218025005380/primarydocument.xml","form_type":"4"}},{"id":1089577,"issuer":{"id":6649,"kind":"organization","name":"Quanterix Corp","symbol":"QTRX"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-11T00:39:39.000Z","date":"2025-07-08","kind":"grant","planned":false,"acquired":true,"shares":2940,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 20,000 shares of Akoya Biosciences, Inc. (\"Akoya\") common stock in connection with the acquisition of Akoya by Quanterix on July 8, 2025. Dr. Lai-Goldman received:  (a) 0.1470 of a share of Quanterix common stock and (b) $0.37 in cash, for each share of Akoya common stock. The closing price of the Quanterix common stock on July 8, 2025 was $6.54 per share. The closing price of the Akoya common stock on July 7, 2025 was $1.29 per share."}],"balance_after":2940,"source":{"system":"sec-edgar","filing":"0001562180-25-005380","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1168581/000156218025005380/primarydocument.xml","form_type":"4"}},{"id":1089576,"issuer":{"id":77553,"kind":"organization","name":"Akoya Biosciences, Inc.","symbol":"AKYA"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-11T00:37:13.000Z","date":"2025-07-08","kind":"other","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Disposition of options pursuant to Merger Agreement."},{"field":"shares","element":"transactionShares","label":"F4","text":"Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":2.01,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001062993-25-012722","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1168581/000106299325012722/form4.xml","form_type":"4"}},{"id":1089575,"issuer":{"id":77553,"kind":"organization","name":"Akoya Biosciences, Inc.","symbol":"AKYA"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-11T00:37:13.000Z","date":"2025-07-08","kind":"other","planned":false,"acquired":false,"shares":56322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Disposition of options pursuant to Merger Agreement."},{"field":"shares","element":"transactionShares","label":"F4","text":"Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":5.7,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":56322},"source":{"system":"sec-edgar","filing":"0001062993-25-012722","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1168581/000106299325012722/form4.xml","form_type":"4"}},{"id":1089574,"issuer":{"id":77553,"kind":"organization","name":"Akoya Biosciences, Inc.","symbol":"AKYA"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-11T00:37:13.000Z","date":"2025-07-08","kind":"other","planned":false,"acquired":false,"shares":30549,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Disposition of options pursuant to Merger Agreement."},{"field":"shares","element":"transactionShares","label":"F4","text":"Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":11.24,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":30549},"source":{"system":"sec-edgar","filing":"0001062993-25-012722","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1168581/000106299325012722/form4.xml","form_type":"4"}},{"id":1089573,"issuer":{"id":77553,"kind":"organization","name":"Akoya Biosciences, Inc.","symbol":"AKYA"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-11T00:37:13.000Z","date":"2025-07-08","kind":"other","planned":false,"acquired":false,"shares":38993,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Disposition of options pursuant to Merger Agreement."},{"field":"shares","element":"transactionShares","label":"F4","text":"Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":18.1,"expiration_date":"2031-09-16","underlying":"Common Stock","underlying_shares":38993},"source":{"system":"sec-edgar","filing":"0001062993-25-012722","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1168581/000106299325012722/form4.xml","form_type":"4"}},{"id":1089572,"issuer":{"id":77553,"kind":"organization","name":"Akoya Biosciences, Inc.","symbol":"AKYA"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-11T00:37:13.000Z","date":"2025-07-08","kind":"other","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the \"Merger Agreement\"), by and among Quanterix Corporation, a Delaware corporation (\"Quanterix\"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix (\"Merger Sub\"), and Issuer. On July 8, 2025 (the \"Closing Date\"), Merger Sub merged with and into Issuer (the \"Merger\"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the \"Per Share Stock Consideration\") and (b) $0.38 in cash, without interest (the \"Per Share Cash Consideration\" and together with the Per Share Stock Consideration, the \"Per Share Merger Consideration\"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-25-012722","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1168581/000106299325012722/form4.xml","form_type":"4"}},{"id":1155703,"issuer":{"id":3201,"kind":"organization","name":"WEST PHARMACEUTICAL SERVICES INC","symbol":"WST"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-08T20:42:06.000Z","date":"2025-05-06","kind":"grant","planned":false,"acquired":true,"shares":1071,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors."}],"balance_after":19423.93,"source":{"system":"sec-edgar","filing":"0001127602-25-013709","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105770/000112760225013709/form4.xml","form_type":"4"}},{"id":1490430,"issuer":{"id":77553,"kind":"organization","name":"Akoya Biosciences, Inc.","symbol":"AKYA"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-05T21:54:11.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 4, 2025, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant."}],"balance_after":50000,"derivative":{"exercise_price":2.01,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-24-068746","document":"tm2416554-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1168581/000110465924068746/tm2416554-2_4seq1.xml","form_type":"4"}},{"id":1535834,"issuer":{"id":3201,"kind":"organization","name":"WEST PHARMACEUTICAL SERVICES INC","symbol":"WST"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-04-25T20:49:32.000Z","date":"2024-04-23","kind":"grant","planned":false,"acquired":true,"shares":564,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors."}],"balance_after":18352.93,"source":{"system":"sec-edgar","filing":"0001127602-24-013406","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105770/000112760224013406/form4.xml","form_type":"4"}},{"id":1859213,"issuer":{"id":77553,"kind":"organization","name":"Akoya Biosciences, Inc.","symbol":"AKYA"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-12T22:18:10.000Z","date":"2023-06-12","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":5,"value":100000.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001104659-23-070484","document":"tm2318472-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1168581/000110465923070484/tm2318472-5_4seq1.xml","form_type":"4"}},{"id":1867591,"issuer":{"id":77553,"kind":"organization","name":"Akoya Biosciences, Inc.","symbol":"AKYA"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-05T21:43:36.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":56322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2024, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant."}],"balance_after":56322,"derivative":{"exercise_price":5.7,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":56322},"source":{"system":"sec-edgar","filing":"0001104659-23-068163","document":"tm2317841-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1168581/000110465923068163/tm2317841-3_4seq1.xml","form_type":"4"}},{"id":1912887,"issuer":{"id":3201,"kind":"organization","name":"WEST PHARMACEUTICAL SERVICES INC","symbol":"WST"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-27T21:16:56.000Z","date":"2023-04-25","kind":"grant","planned":false,"acquired":true,"shares":616,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of restricted stock units will vest in full on the first anniversary of the date of the grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors."}],"balance_after":17788.93,"source":{"system":"sec-edgar","filing":"0001562180-23-003696","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105770/000156218023003696/primarydocument.xml","form_type":"4"}},{"id":2245356,"issuer":{"id":77553,"kind":"organization","name":"Akoya Biosciences, Inc.","symbol":"AKYA"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy","published_at":"2022-06-03T20:06:34.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":30549,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2023, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant."}],"balance_after":30549,"derivative":{"exercise_price":11.24,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":30549},"source":{"system":"sec-edgar","filing":"0001104659-22-068077","document":"tm2217652-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1168581/000110465922068077/tm2217652-5_4seq1.xml","form_type":"4"}},{"id":2256186,"issuer":{"id":3201,"kind":"organization","name":"WEST PHARMACEUTICAL SERVICES INC","symbol":"WST"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-26T19:49:04.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":632,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors."}],"balance_after":17172.93,"source":{"system":"sec-edgar","filing":"0001562180-22-004429","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105770/000156218022004429/primarydocument.xml","form_type":"4"}},{"id":2564204,"issuer":{"id":77553,"kind":"organization","name":"Akoya Biosciences, Inc.","symbol":"AKYA"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy","published_at":"2021-09-21T00:51:43.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":38993,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuous service through the vesting date, the options shall vest in three (3) equal installments beginning on September 16, 2022 and annually thereafter until fully vested."}],"balance_after":38993,"derivative":{"exercise_price":18.1,"expiration_date":"2031-09-16","underlying":"Common Stock","underlying_shares":38993},"source":{"system":"sec-edgar","filing":"0001104659-21-117549","document":"tm2128081-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1168581/000110465921117549/tm2128081-2_4seq1.xml","form_type":"4"}},{"id":2725929,"issuer":{"id":3201,"kind":"organization","name":"WEST PHARMACEUTICAL SERVICES INC","symbol":"WST"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-06T23:28:59.000Z","date":"2021-05-04","kind":"grant","acquired":true,"shares":577,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects additional shares purchased through dividend reinvestments based on most recent plan statement."}],"balance_after":16540.93,"source":{"system":"sec-edgar","filing":"0001562180-21-003309","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105770/000156218021003309/primarydocument.xml","form_type":"4"}},{"id":3158878,"issuer":{"id":3201,"kind":"organization","name":"WEST PHARMACEUTICAL SERVICES INC","symbol":"WST"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-07T22:06:48.000Z","date":"2020-05-05","kind":"grant","acquired":true,"shares":975,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects additional shares purchased through dividend reinvestments based on most recent plan statement."}],"balance_after":15927.5992,"source":{"system":"sec-edgar","filing":"0001562180-20-003466","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105770/000156218020003466/primarydocument.xml","form_type":"4"}},{"id":3534355,"issuer":{"id":3201,"kind":"organization","name":"WEST PHARMACEUTICAL SERVICES INC","symbol":"WST"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-09T19:11:02.000Z","date":"2019-05-07","kind":"grant","acquired":true,"shares":1565,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects additional shares purchased through dividend reinvestments based on most recent plan statement."}],"balance_after":12943.0115,"source":{"system":"sec-edgar","filing":"0001562180-19-002730","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105770/000156218019002730/primarydocument.xml","form_type":"4"}},{"id":3857375,"issuer":{"id":3201,"kind":"organization","name":"WEST PHARMACEUTICAL SERVICES INC","symbol":"WST"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock Unit","published_at":"2018-08-01T20:35:23.000Z","date":"2017-12-29","kind":"grant","acquired":true,"shares":103.2362,"price":99.16,"value":10236.901592,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."}],"balance_after":1832.0826,"derivative":{"underlying":"Common Stock","underlying_shares":103.2362},"source":{"system":"sec-edgar","filing":"0001562180-18-003449","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/105770/000156218018003449/primarydocument.xml","form_type":"4"}},{"id":3949031,"issuer":{"id":3201,"kind":"organization","name":"WEST PHARMACEUTICAL SERVICES INC","symbol":"WST"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-03T21:45:50.000Z","date":"2018-05-01","kind":"grant","acquired":true,"shares":1824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of restricted stock units will vest in full on the first anniversay of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares of restricted stock units will vest in full on the first anniversay of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors."}],"balance_after":11378.0115,"source":{"system":"sec-edgar","filing":"0001562180-18-002196","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105770/000156218018002196/primarydocument.xml","form_type":"4"}},{"id":4196561,"issuer":{"id":3201,"kind":"organization","name":"WEST PHARMACEUTICAL SERVICES INC","symbol":"WST"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock Unit","published_at":"2017-10-03T19:53:25.000Z","date":"2017-09-29","kind":"grant","acquired":true,"shares":103.8098,"price":96.33,"value":9999.998034,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects additional shares purchased through dividend reinvestments based on most recent plan statement."}],"balance_after":1728.8464,"derivative":{"underlying":"Common Stock","underlying_shares":103.8098},"source":{"system":"sec-edgar","filing":"0001562180-17-003161","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/105770/000156218017003161/primarydocument.xml","form_type":"4"}},{"id":4266697,"issuer":{"id":3201,"kind":"organization","name":"WEST PHARMACEUTICAL SERVICES INC","symbol":"WST"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock Unit","published_at":"2017-07-05T16:39:11.000Z","date":"2017-06-30","kind":"grant","acquired":true,"shares":105.9434,"price":94.39,"value":9999.997526,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects additional shares purchased through dividend reinvestments based on most recent plan statement."}],"balance_after":1622.6151,"derivative":{"underlying":"Common Stock","underlying_shares":105.9434},"source":{"system":"sec-edgar","filing":"0001562180-17-002374","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/105770/000156218017002374/primarydocument.xml","form_type":"4"}},{"id":4336642,"issuer":{"id":3201,"kind":"organization","name":"WEST PHARMACEUTICAL SERVICES INC","symbol":"WST"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-03T18:56:51.000Z","date":"2017-05-02","kind":"grant","acquired":true,"shares":1697,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of restricted stock units will vest in full after 12 months and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors."}],"balance_after":9528.9468,"source":{"system":"sec-edgar","filing":"0001562180-17-001689","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105770/000156218017001689/primarydocument.xml","form_type":"4"}},{"id":4363886,"issuer":{"id":3201,"kind":"organization","name":"WEST PHARMACEUTICAL SERVICES INC","symbol":"WST"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock Unit","published_at":"2017-04-04T19:16:49.000Z","date":"2017-03-31","kind":"grant","acquired":true,"shares":122.414,"price":81.69,"value":9999.99966,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects additional shares purchased through dividend reinvestments based on most recent plan statement."}],"balance_after":1514.5777,"derivative":{"underlying":"Common Stock","underlying_shares":122.414},"source":{"system":"sec-edgar","filing":"0001562180-17-001423","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/105770/000156218017001423/primarydocument.xml","form_type":"4"}},{"id":4506131,"issuer":{"id":3201,"kind":"organization","name":"WEST PHARMACEUTICAL SERVICES INC","symbol":"WST"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock Unit","published_at":"2017-01-04T19:56:53.000Z","date":"2016-12-30","kind":"grant","acquired":true,"shares":117.3709,"price":85.2,"value":10000.00068,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects additional shares purchased through dividend reinvestments based on most recent plan statement."}],"balance_after":1390.028,"derivative":{"underlying":"Common Stock","underlying_shares":117.3709},"source":{"system":"sec-edgar","filing":"0001562180-17-000145","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/105770/000156218017000145/primarydocument.xml","form_type":"4"}},{"id":4589053,"issuer":{"id":3201,"kind":"organization","name":"WEST PHARMACEUTICAL SERVICES INC","symbol":"WST"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true}}],"security":"Phantom Stock Unit","published_at":"2016-10-04T19:07:31.000Z","date":"2016-09-30","kind":"grant","acquired":true,"shares":134.9164,"price":74.12,"value":10000.003568,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects additional shares purchased through dividend reinvestments based on most recent plan statement."}],"balance_after":1268.7644,"derivative":{"underlying":"Common Stock","underlying_shares":134.9164},"source":{"system":"sec-edgar","filing":"0001225208-16-039974","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/105770/000122520816039974/doc4.xml","form_type":"4"}},{"id":4609732,"issuer":{"id":182543,"kind":"organization","name":"SEQUENOM INC","symbol":"SQNM"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2016-09-07T16:34:08.000Z","date":"2016-09-07","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option.  In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option.  In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":1.11,"expiration_date":"2026-06-14","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-16-140402","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1076481/000120919116140402/doc4.xml","form_type":"4"}},{"id":4609731,"issuer":{"id":182543,"kind":"organization","name":"SEQUENOM INC","symbol":"SQNM"},"owners":[{"id":31274,"kind":"person","name":"LAI GOLDMAN MYLA","position":1,"cik":"0001168581","reported_name":"LAI GOLDMAN MYLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-09-07T16:34:08.000Z","date":"2016-09-07","kind":"other","acquired":false,"shares":79579,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation (\"Parent\"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-16-140402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076481/000120919116140402/doc4.xml","form_type":"4"}}]}